Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for SUNPHARMA
Revenue projections for SUNPHARMA

Investors may be wary of SUNPHARMA as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 28.046993
debtToEquity 3.259000
earningsGrowth -0.195000
revenueGrowth 0.095000
grossMargins 0.782480
operatingMargins 0.243450
trailingEps 43.250000
forwardEps 32.680000

With SUNPHARMA's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
SUNPHARMA's low growth in both earnings and revenue indicates potential profit shrinkage. This downward trend could be a sign of weakening financial health, signaling challenges for the company's future profitability.
Sun Pharmaceutical Industries Limited's positive gross and operating margins highlight its strong profitability. The company's ability to control costs while generating revenue indicates efficient operations and a healthy financial position.
SUNPHARMA's lower forward EPS compared to trailing EPS suggests the company's earnings are expected to decline. This indicates that SUNPHARMA may be less profitable in the upcoming year, raising questions about its financial trajectory.

Price projections:

Price projections for SUNPHARMA
Price projections for SUNPHARMA

Over time, analysts have gradually revised SUNPHARMA's price projections downward. This suggests growing concerns about the company's ability to meet previous expectations, pointing to a more conservative outlook.

Recommendation changes over time:

Recommendations trend for SUNPHARMA
Recommendations trend for SUNPHARMA


A recent buy bias from analysts toward SUNPHARMA indicates strong confidence in the stock's future performance. This could encourage investors to park their money in SUNPHARMA, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.